Binds Parasitic Organism (i.e., Parasitic Protozoan, Multicellular Ectoparasite (e.g., Flea, Tick, Mite, Etc.), Or Multicellular Endoparasite (e.g., Parasitic Worm, Etc.)) Or Component Thereof Or Substance Produced By Said Parasitic Organism Patents (Class 424/151.1)
  • Patent number: 9034338
    Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
  • Patent number: 9034339
    Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
  • Patent number: 8865165
    Abstract: This present invention discloses a monoclonal antibody which specifically recognizes and binds to a epitope of group 2 allergen of Dermatophagoides pteronyssiuns, usually named Der p 2, and a hybridoma cell line producing thereof. Furthermore, this invention also discloses a strip, kit and method utilizing said monoclonal antibody for the detection of the presence of dust mite allergens and the calculation of dust mite number in the environment.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: October 21, 2014
    Assignee: Taichung Veterans General Hospital
    Inventors: En-Chin Liao, Jaw-Ji Tsai
  • Patent number: 8852596
    Abstract: Immunolocalization of ?- and ?-giardin in Giardia lamblia trophozoites revealed that both giardins are strictly associated with the ventral disc. Optical sectioning of immunolabeled ventral disc, together with quantitative co-localization of ?- and ?-giardin immunoreactivity, demonstrated that ?-giardin is primarily localized to the ventral side, and ?-giardin is localized to the dorsal side of the ventral disc. Antibodies to ?-giardin and ?-giardin can both be used as diagnostic agents; anti-?-giardin antibody can be used as a therapeutic reagent to inhibit binding of trophozoites to host cells.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: October 7, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Mark C. Jenkins, Ronald Fayer, Monica Santin, Dumitru Macarisin, Celia O'Brien
  • Patent number: 8715751
    Abstract: The invention relates to the treatment of kintoplastid infections by administering a pharmaceutical composition containing an extract from the plant Artemisia annua. The invention also relates to isolated, semi-synthetic and synthetic artemisinins that show improved efficacy in treating kinetoplastid infections. This invention also relates to a method of treating kintoplastid infections with artelinic acid and artemisinins and where Artelinic acid is administered orally.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: May 6, 2014
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Bruno K. Kubata, Samuel K. Martin, Wilbur K. Milhous
  • Patent number: 8703134
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 22, 2014
    Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Patent number: 8501183
    Abstract: The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol (“GPI”) inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by Plasmodium species. The invention also provides a method of monitoring, or qualitatively or quantitatively assessing an immune response to a microorganism such as a parasite.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: August 6, 2013
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventor: Louis Schofield
  • Patent number: 8460890
    Abstract: This invention provides compositions and methods for detection of hematophagous ectoparasitic activity in an enclosure or area. The compositions comprise a reagent or reagents which are reactive against antigens or markers as they appear in the excrement or other ectoparasitic materials. Such markers or antigens may be produced by the ectoparasite itself or may have been introduced into the ectoparasite because of its blood feeding activity. The method of the present invention comprises collecting from the enclosure or area, a sample comprising environmental dust or materials and subjecting the sample to tests for detecting the presence of hematophagous ectoparasitic markers, host markers or both.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: June 11, 2013
    Assignee: Cytosignet, Inc.
    Inventor: Nathan L. Smith
  • Patent number: 8409817
    Abstract: The invention provides methods and compositions for the detection of Ehrlichia chaffeensis.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: April 2, 2013
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Thomas Patrick O'Connor, Jr., Eugene Regis Krah, III, Jill M. Saucier
  • Patent number: 8394379
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 12, 2013
    Assignee: ioGenetics, LLC
    Inventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
  • Patent number: 8367808
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of whipworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of whipworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, roundworm, and heartworm. Confirmation of the presence or absence of whipworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: February 5, 2013
    Assignees: IDEXX Laboratories, Inc., Divergence, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn, Michael Crawford
  • Publication number: 20130022612
    Abstract: A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition.
    Type: Application
    Filed: September 24, 2012
    Publication date: January 24, 2013
    Applicant: NEW YORK UNIVERSITY
    Inventor: NEW YORK UNIVERSITY
  • Patent number: 8148057
    Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: April 3, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Arnold R. Castro
  • Publication number: 20120039984
    Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.
    Type: Application
    Filed: July 2, 2009
    Publication date: February 16, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
  • Patent number: 8110188
    Abstract: The invention refers to anticoccidial compositions consisting mainly of yolk immunoglobulins derived from eggs of hens immunized with one or more Eimeria species. The invention refers also to the use of said anticoccidial compositions for prevention or treatment of coccidiosis. The administration of immunoglobulins, both in liquid as well as in powder or pellet presentation, decreases mortality, lesions, oocysts counts and increases weight gain of receiving animals.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: February 7, 2012
    Assignee: Investigacion Aplicada, S.A. de C.V.
    Inventors: Jose Andres Morales Garzon, Eduardo Lucio Decanini
  • Patent number: 8097261
    Abstract: A composition, device, kit and method for detecting the presence or absence of roundworm in a fecal sample. The composition, device, kit and method of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: January 17, 2012
    Assignee: Idexx Laboratories, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn
  • Patent number: 7964366
    Abstract: The invention provides methods and compositions for the detection of Ehrlichia chaffeensis.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 21, 2011
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Thomas Patrick O'Connor, Jr., Eugene Regis Krah, III, Jill M. Saucier
  • Patent number: 7811569
    Abstract: The present invention relates to a recombinant human antibody comprising an antibodysequence specific for the MSP-3 antigen of Plasmodium falciparum. In particular, the invention relates to a recombinant human antibody which is specific for the MSP-3194-257 antigen. The invention further relates to nucleic acid encoding such antibodies and to uses of these antibodies, in particular in the treatment or prophylaxis of malaria.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: October 12, 2010
    Assignee: Institut Pasteur
    Inventors: Morten Steen Hanefeld Dziegiel, Rasmus Lundquist, Leif Kofoed Nielsen, Pierre Druilhe
  • Patent number: 7736660
    Abstract: A composition, device, kit and method for detecting the presence or absence of roundworm in a fecal sample. The composition, device, kit and method of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: June 15, 2010
    Assignee: IDEXX Laboratories, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn
  • Publication number: 20100040615
    Abstract: The invention relates to a digalactolipidic antigen exposed on the surface of apicomplex parasites, in the form of a vegetable-type digalactoglycerolipid, and adapted for inducing the production of specific antibodies capable of inhibiting the proliferation and/or the invasive properties of said parasites; the invention also relates to a derived antibody or functional antibody fragment, and to their diagnostic, immunotherapeutic and vaccine applications in human beings or animals.
    Type: Application
    Filed: February 7, 2008
    Publication date: February 18, 2010
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SEIENTIFIQUE
    Inventors: Cyrille Botte, Nadia Saidani, Maryse Block, Jean-Francois Dubremetz, Henri Vial, Marie-France Cesbron-Delauw, Corinne Mercier, Eric Marechal
  • Publication number: 20100034824
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: August 5, 2009
    Publication date: February 11, 2010
    Applicants: IOGENETICS, LLC, THE ARIZONA BOARD OF REGENTS
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer
  • Patent number: 7563440
    Abstract: The invention provides novel preparations for a broad-spectrum antiplasmodial vaccine.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: July 21, 2009
    Assignee: Institut Pasteur
    Inventor: Pierre Druilhe
  • Patent number: 7462359
    Abstract: A Neospora caninum vaccine comprising tissue culture grown Neospora and methods of making and using said vaccines. Neospora caninum vaccines described include those containing whole Neospora tachyzoites, extracts of Neospora tachyzoites and protective antigen subunits of Neospora tachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: December 9, 2008
    Assignee: Intervet International B.V.
    Inventors: Leszek J. Choromanski, Karen K. Brown
  • Publication number: 20080260750
    Abstract: The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that modulate the acetylcholine-gated chloride channels are provided.
    Type: Application
    Filed: June 8, 2005
    Publication date: October 23, 2008
    Inventors: Joseph Alan Dent, Igor Putrenko
  • Patent number: 7429381
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: September 30, 2008
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7410771
    Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.
    Type: Grant
    Filed: April 14, 2006
    Date of Patent: August 12, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock
  • Patent number: 7390626
    Abstract: ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 24, 2008
    Assignee: Immunosciences Lab., Inc.
    Inventor: Aristo Vojdani
  • Patent number: 7317094
    Abstract: The process of the invention comprises the implementation of axenic conditions, with use of a liquid single-phase culture medium. For obtaining the amastigote forms, this medium is buffered at a pH of 5.5 to 6.5 and has an osmolarity of at least 400 milliosmoles/kg of liquid, and in particular 400 to 550 milliosmoles/kg of liquid. For obtaining promastigote forms, this medium is buffered at a pH of 7 to 7.5 and has an osmolarity of at least 300 milliosmoles/kg of liquid. This process allows the adaptation and culture in vitro of different stages of tissular parasites, such as leishmanias and T. cruzi or also hematoprotozoa.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: January 8, 2008
    Assignee: Institut Francais de Recherche Scientifique pour le Developpement en Cooperation (Orstom)
    Inventor: Jean-Loup Lemesre
  • Patent number: 7211256
    Abstract: The present invention relates, in part, to a purified polyclonal or monoclonal antibody which recognizes an epitope of a protein of 48,000 dalton, where the protein recognizes is a surface protein of a merozoite of Plasmodium falciparum which has a peptide of SEQ ID NO:1 or a sequence wherein SEQ ID NO:1 has been modified by insertion, deletion or substitution and the sequence inhibits the binding of monoclonal antibody 245 to Plasmodium merozoites, as well as fragments of the antibody; the present invention relates to composition and kits containing the same, as well as methods of using the same.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: May 1, 2007
    Assignee: Institut Pasteur
    Inventors: Pierre Druilhe, Hasnaq Bouharoun-Tayoun, Claude Oeuvray
  • Patent number: 7063844
    Abstract: Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: June 20, 2006
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Steven A. Porcelli, Michael B. Brenner, Evan M. Beckman, Stephen T. Furlong
  • Patent number: 7025961
    Abstract: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes are provided. More particularly, antibodies specific for Plasmodium falciparum binding proteins and blocking peptides that prevent the binding of Plasmodium falciparum are included in the present invention. The methods provided utilize the antibody and peptide compositions provided herein and include methods for the diagnosis, prevention, and treatment of Plasmodium falciparum diseases such as malaria as well as methods for the detection of Plasmodium falciparum in biological samples and culture media.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: April 11, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David L. Narum, Kim Lee Sim
  • Patent number: 6936247
    Abstract: The present invention relates to isolated parasitic helminth nucleic acid sequences capable of hybridizing, under stringent conditions, to at least a portion of D. immitis nucleic acid sequence p4 and/or to at least a portion of D. immitis nucleic acid sequence p22U; to isolated parasitic helminth proteins that are encoded by such parasitic helminth nucleic acid sequences and that are capable of selectively binding to at least one component of immune serum capable of inhibiting helminth development; and to antibodies raised against such isolated parasitic helminth proteins. The present invention also relates to therapeutic compositions comprising such isolated nucleic acid sequences, proteins and/or antibodies. The present invention also includes methods to produce and use such nucleic acids, proteins, antibodies and therapeutic compositions capable of protecting animals from parasitic helminth infection and, particularly, from heartworm, infection.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: August 30, 2005
    Assignees: Heska Corporation, Colorado State University Research Foundation
    Inventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
  • Patent number: 6891024
    Abstract: The present invention is directed to particular monoclonal antibodies that find use in the identification and purification of Sarcocystis neurona and related antigens. In particular, these antibodies permit the diagnosis of Sarcocystis related diseases such as equine protozoal myeloencephalitis (EPM).
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: May 10, 2005
    Assignee: The Curators of the University of Missouri
    Inventor: Antoinette Marsh
  • Patent number: 6852319
    Abstract: The present invention relates to expression and assembly of foreign multimeric proteins—e.g., antibodies—in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional secretory antibodies in plants is disclosed. The invention also discloses compositions produced by the transgenic plants of the present invention and methods of using same.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: February 8, 2005
    Assignee: The Scripps Research Institue
    Inventors: Mich B. Hein, Andrew Hiatt, Julian K-C Ma
  • Patent number: 6828416
    Abstract: A recombinant protein is provided which comprises peptides derived from different stages in the life cycle of parasite Plasmodium falciparum. The protein is useful as a reagent and, when combined with a pharmaceutically-acceptable vehicle or carrier, is useful as a vaccine against the material parasite Plasmodium falciparum. A genetic construct used to produce this recombinant protein vaccine is also described. In addition, antibodies to this recombinant protein are provided which are useful for the detection and measurement of peptides derived from different stages in the life cycle of the parasite Plasmodium falciparum.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: December 7, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Altaf A. Lal, Ya Ping Shi, Seyed E. Hasnain
  • Patent number: 6803035
    Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: October 12, 2004
    Assignee: Arkion Life Sciences
    Inventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
  • Publication number: 20040185050
    Abstract: A method for the prevention of infection of humans by plasmodium parasites is provided. The method consists of the application of compounds that interfere with the infection of hepatocytes by Plasmodium viax.
    Type: Application
    Filed: March 9, 2004
    Publication date: September 23, 2004
    Inventors: Maria M. Mota, Ana Rodriguez, Silvia Giordano, Margarida Cunha Rodrigues
  • Patent number: 6777222
    Abstract: A method of producing IgG1 subclass antibodies reactive to the surface of Crystosporidium oocysts, the method comprising: (a) separating at least a protion of the Cryptosporidium oocyst wall from the internal sporozoites to form an oocyst-wall preparation; (b) treating the separated oocyst-wall preparation so as to obtain an oocyst antigen preparation capable of eliciting a detectable IgG1 immune response in an animal to the surface of the oocyst; (c) immunizing an animal with the oocyst antigen preparation so as to elicit an IgG1 immune response in the animal; and (d) obtaining from the animal IgG1 antibodies reactive to the surface of Cryptosporidium oocysts. IgG1 antibodies reactive to the surface of Cryptosporidium oocysts.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: August 17, 2004
    Assignees: Macquarie Research Ltd., Sydney Water Corporation
    Inventors: Graham Vesey, Christopher Weir, Keith Leslie Williams, Martin Basil Slade, Duncan Veal
  • Patent number: 6730307
    Abstract: Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: May 4, 2004
    Assignees: The Arizona Board of Regents Acting on Behalf of the University of Arizona, North Carolina State University
    Inventors: Michael W. Riggs, Lance E. Perryman
  • Patent number: 6719975
    Abstract: A method of making antibodies to hirudin by immunizing with an immunogenic composition containing polymerized hirudin monomers in the absence of carrier protein is taught.
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: April 13, 2004
    Assignee: Farmitalia Carlo Erba S.r.l.
    Inventors: Antonio Molinari, Marco Gerna, Carla Giorgetti, Jacqueline Lansen, Romeo Roncucci
  • Publication number: 20040062769
    Abstract: The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.
    Type: Application
    Filed: February 21, 2002
    Publication date: April 1, 2004
    Inventors: Arthur Scherf, Louis H. Miller, Benoit Gamain, Dror I. Baruch, Pierre Buffet, Christine Scheidig, Jurg Gysin, Bruno Pouvelle, Nobutaka Fujii, Joseph Smith
  • Patent number: 6710166
    Abstract: Recombinant proteins have been developed for the immunization of animals against cryptosporidiosis. The proteins are effective for the immunization of a variety of animals against Cryptosporidium parvum, particularly for the production of hyperimmune colostrum that may be used to confer passive immunity against the parasite. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: March 23, 2004
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Mark C. Jenkins, Ron Fayer, James Trout
  • Patent number: 6682737
    Abstract: Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: January 27, 2004
    Assignee: North Carolina State University
    Inventors: Michael W. Riggs, Lance E. Perryman
  • Patent number: 6673345
    Abstract: The present invention relates to parasite astacin metalloendopeptidase proteins, nucleic acid molecules having sequences that encode such proteins, antibodies raised against such proteins and compounds that can inhibit the activities of parasite astacin metalloendopeptidases. The present invention also includes methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitors. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites, such as heartworm infection.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: January 6, 2004
    Assignee: Heska Corporation
    Inventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
  • Patent number: 6627196
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: September 30, 2003
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Publication number: 20030103977
    Abstract: This invention relates to monoclonal antibodies which bind to non-enhancing protective epitopes on serotype A, B, C and D strains of C. neoformans, such protective epitopes containing acetyl groups in the polysaccharide of the epitopes. Other monoclonal antibodies of this invention are serotype specific, and bind to acetyl groups on polysaccharide capsule protective epitopes of serotype D strain C. neoformans only. This invention further relates to methods for producing these monoclonal antibodies. These monoclonal antibodies may be passively administered to treat and prevent cryptococcal infection, such as Cryptococcal meningitis, in immunosuppressed patients. These monoclonal antibodies may also be used for detection of fungal infection, for the development of diagnostic serotyping of clinical isolates, and as therapeutic adjuncts to anti-fungal antibiotic therapy.
    Type: Application
    Filed: September 24, 2002
    Publication date: June 5, 2003
    Inventors: Arturo Casadevall, Matthew D. Scharff, Jean Mukherjee
  • Patent number: 6521229
    Abstract: Recombinant proteins have been developed for the immunization of animals against cryptosporidiosis. The proteins are effective for the immunization of a variety of animals against Cryptosporidium parvum, particularly for the production of hyperimmune colostrum that may be used to confer passive immunity against the parasite. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of cells and the production of the proteins.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: February 18, 2003
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Mark C. Jenkins, Ronald Fayer, James Trout
  • Patent number: 6514963
    Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: February 4, 2003
    Assignee: The Regents of the University of California
    Inventors: Mark Walter, Armand Kuris
  • Patent number: 6489448
    Abstract: The present invention relates to parasitic helminth thiol specific antioxidant (TSA) larval proteins; to parasitic helminth larval TSA nucleic acid molecules, including those that encode such TSA proteins; to antibodies raised against such TSA proteins; and to compounds that inhibit parasitic helminth larval TSA activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.
    Type: Grant
    Filed: January 4, 2000
    Date of Patent: December 3, 2002
    Assignee: Heska Corporation
    Inventors: Laura Klimowski, Cynthia Ann Tripp
  • Patent number: 6458933
    Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: October 1, 2002
    Assignee: Immunomedics, Inc.
    Inventor: Hans J. Hansen